Hydrodynamic transfection for generation of novel mouse models for liver cancer research.

[1]  D. Calvisi,et al.  On the role of notch1 and adult hepatocytes in murine intrahepatic cholangiocarcinoma development , 2013, Hepatology.

[2]  J. Llovet,et al.  Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies , 2013, Oncogene.

[3]  M. Manns,et al.  Adjuvant gemcitabine therapy improves survival in a locally induced, R0‐resectable model of metastatic intrahepatic cholangiocarcinoma , 2013, Hepatology.

[4]  D. Calvisi,et al.  Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis , 2013, Cell cycle.

[5]  R. Schmid,et al.  Canonical Notch2 signaling determines biliary cell fates of embryonic hepatoblasts and adult hepatocytes independent of Hes1 , 2013, Hepatology.

[6]  M. Manns,et al.  A Direct In Vivo RNAi Screen Identifies MKK4 as a Key Regulator of Liver Regeneration , 2013, Cell.

[7]  T. Scheetz,et al.  Identification of Rtl1, a Retrotransposon-Derived Imprinted Gene, as a Novel Driver of Hepatocarcinogenesis , 2013, PLoS genetics.

[8]  E. Wagner,et al.  Mouse models for liver cancer , 2013, Molecular oncology.

[9]  J. Seong,et al.  Investigation of Oncogenic Cooperation in Simple Liver-Specific Transgenic Mouse Models Using Noninvasive In Vivo Imaging , 2013, PloS one.

[10]  Sayaka Sekiya,et al.  Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. , 2012, The Journal of clinical investigation.

[11]  Edward Kai-Hua Chow,et al.  Oncogene‐specific formation of chemoresistant murine hepatic cancer stem cells , 2012, Hepatology.

[12]  D. Calvisi,et al.  Bmi1 Is Required for Hepatic Progenitor Cell Expansion and Liver Tumor Development , 2012, PloS one.

[13]  D. Calvisi,et al.  Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis via activation of MAPK and PKM2 pathways. , 2012, Journal of hepatology.

[14]  G. Gores,et al.  Cholangiocarcinomas can originate from hepatocytes in mice. , 2012, The Journal of clinical investigation.

[15]  W. Palmer,et al.  Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. , 2012, Journal of hepatology.

[16]  E. Brunt,et al.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. , 2012, Journal of hepatology.

[17]  David V Schaffer,et al.  The AAV Vector Toolkit: Poised at the Clinical Crossroads. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[18]  D. Calvisi,et al.  AKT (v‐akt murine thymoma viral oncogene homolog 1) and N‐Ras (neuroblastoma ras viral oncogene homolog) coactivation in the mouse liver promotes rapid carcinogenesis by way of mTOR (mammalian target of rapamycin complex 1), FOXM1 (forkhead box M1)/SKP2, and c‐Myc pathways , 2012, Hepatology.

[19]  M. Saleem,et al.  CANCER STEM CELLS Concise Review: Role of BMI1, a Stem Cell Factor, in Cancer Recurrence and Chemoresistance: Preclinical and Clinical Evidences , 2012 .

[20]  N. Ferry,et al.  Priming of hepatocytes enhances in vivo liver transduction with lentiviral vectors in adult mice. , 2012, Human gene therapy methods.

[21]  T. Luedde,et al.  Senescence surveillance of pre-malignant hepatocytes limits liver cancer development , 2011, Nature.

[22]  W. Yeo,et al.  Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. , 2011, Future oncology.

[23]  H. El‐Serag,et al.  Risk factors for cholangiocarcinoma , 2011, Hepatology.

[24]  G. Gores,et al.  Strategies for hepatocellular carcinoma therapy and diagnostics: Lessons learned from high throughput and profiling approaches , 2011, Hepatology.

[25]  J. Zucman‐Rossi,et al.  Genetics of Hepatobiliary Carcinogenesis , 2011, Seminars in liver disease.

[26]  S. Thorgeirsson,et al.  Exploring genomic profiles of hepatocellular carcinoma , 2011, Molecular carcinogenesis.

[27]  S. Thorgeirsson,et al.  Coactivation of AKT and β-catenin in mice rapidly induces formation of lipogenic liver tumors. , 2011, Cancer research.

[28]  T. Patel,et al.  Cholangiocarcinoma—controversies and challenges , 2011, Nature Reviews Gastroenterology &Hepatology.

[29]  D. Largaespada,et al.  Modeling hepatitis B virus X–induced hepatocellular carcinoma in mice with the sleeping beauty transposon system , 2011, Hepatology.

[30]  D. Calvisi,et al.  Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma. , 2011, Gastroenterology.

[31]  H. Janssen,et al.  AAV-mediated gene therapy for liver diseases: the prime candidate for clinical application? , 2011, Expert opinion on biological therapy.

[32]  F. Al-Kawas,et al.  Cholangiocarcinoma: Epidemiology, Risk Factors, Pathogenesis, and Diagnosis , 2011, Current gastroenterology reports.

[33]  Tushar Patel,et al.  Targeting the IL-6 Dependent Phenotype Can Identify Novel Therapies for Cholangiocarcinoma , 2010, PloS one.

[34]  D. Sabatini,et al.  mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.

[35]  D. Calvisi,et al.  Synergistic role of sprouty2 inactivation and c‐Met up‐regulation in mouse and human hepatocarcinogenesis , 2010, Hepatology.

[36]  Derek Y. Chiang,et al.  Cancer gene discovery in hepatocellular carcinoma. , 2010, Journal of hepatology.

[37]  N. Fausto,et al.  Mouse Models of Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[38]  Xin Chen,et al.  Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis , 2009, Molecular Cancer Research.

[39]  F. Heindryckx,et al.  Experimental mouse models for hepatocellular carcinoma research , 2009, International journal of experimental pathology.

[40]  I. McKillop,et al.  Role of alcohol in liver carcinogenesis. , 2009, Seminars in liver disease.

[41]  S. Hirohashi,et al.  Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma , 2009, British Journal of Cancer.

[42]  Yu Wei,et al.  Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. , 2008, Cancer cell.

[43]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[44]  J. Furuse.  Sorafenib for the treatment of unresectable hepatocellular carcinoma , 2008, Biologics : targets & therapy.

[45]  A. Iwama,et al.  The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. , 2008, Cancer research.

[46]  D. Mccarty.  Self-complementary AAV vectors; advances and applications. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  G. Gores,et al.  Cholangiocarcinoma: Advances in pathogenesis, diagnosis, and treatment , 2008, Hepatology.

[48]  D. Largaespada,et al.  A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver , 2008, Hepatology.

[49]  Jane Fridlyand,et al.  Integration of genomic analysis and in vivo transfection to identify sprouty 2 as a candidate tumor suppressor in liver cancer , 2007, Hepatology.

[50]  M. Kay,et al.  Distinct pathways of genomic progression to benign and malignant tumors of the liver , 2007, Proceedings of the National Academy of Sciences.

[51]  S. Thorgeirsson,et al.  Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. , 2007, The Journal of clinical investigation.

[52]  S. Glaser,et al.  Molecular pathology of biliary tract cancers. , 2007, Cancer letters.

[53]  S. Monga,et al.  WNT/β‐catenin signaling in liver health and disease , 2007 .

[54]  M. Clarke,et al.  Cancer stem cells: models and concepts. , 2007, Annual review of medicine.

[55]  G. Gores,et al.  Induction of intrahepatic cholangiocellular carcinoma by liver-specific disruption of Smad4 and Pten in mice. , 2006, The Journal of clinical investigation.

[56]  Tetsuhiro Chiba,et al.  Side population purified from hepatocellular carcinoma cells harbors cancer stem cell–like properties , 2006, Hepatology.

[57]  R. DePinho,et al.  Chronic bile duct injury associated with fibrotic matrix microenvironment provokes cholangiocarcinoma in p53-deficient mice. , 2006, Cancer research.

[58]  M. Wigler,et al.  Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach , 2006, Cell.

[59]  Tushar Patel,et al.  Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. , 2006, Gastroenterology.

[60]  E. Sausville,et al.  Contributions of human tumor xenografts to anticancer drug development. , 2006, Cancer research.

[61]  S. So,et al.  Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. , 2006, Cancer research.

[62]  T. Patel,et al.  gamma-Aminobutyric acid inhibits cholangiocarcinoma growth by cyclic AMP-dependent regulation of the protein kinase A/extracellular signal-regulated kinase 1/2 pathway. , 2005, Cancer research.

[63]  Corey M. Carlson,et al.  Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  G. Martin,et al.  Sprouty2, a mouse deafness gene, regulates cell fate decisions in the auditory sensory epithelium by antagonizing FGF signaling. , 2005, Developmental cell.

[65]  M. Yeh,et al.  Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Eric C. Olivares,et al.  In Vivo Correction of Murine Hereditary Tyrosinemia Type I by ϕC31 Integrase-Mediated Gene Delivery. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[67]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[68]  T. Putti,et al.  The Ras/Mitogen-Activated Protein Kinase Pathway Inhibitor and Likely Tumor Suppressor Proteins, Sprouty 1 and Sprouty 2 Are Deregulated in Breast Cancer , 2004, Cancer Research.

[69]  T. Mak,et al.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. , 2004, The Journal of clinical investigation.

[70]  D. Stolz,et al.  Hydroporation as the mechanism of hydrodynamic delivery , 2004, Gene Therapy.

[71]  M. Bibby,et al.  Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. , 2004, European journal of cancer.

[72]  M. Taketo,et al.  Hepatocarcinogenesis in Mice with β-Catenin and Ha-Ras Gene Mutations , 2004, Cancer Research.

[73]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. , 2003, The American journal of pathology.

[74]  M. Kay,et al.  Helper-independent Sleeping Beauty Transposon–transposase Vectors for Efficient Nonviral Gene Delivery and Persistent Gene Expression in Vivo , 2022 .

[75]  L. Seymour,et al.  Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[76]  J. Herman,et al.  Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. , 2003, The American journal of pathology.

[77]  M. Kay,et al.  In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[78]  H. El‐Serag.  Hepatocellular carcinoma: an epidemiologic view. , 2002, Journal of clinical gastroenterology.

[79]  S. Thorgeirsson,et al.  Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.

[80]  B. Torok-Storb,et al.  The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. , 2002, Blood.

[81]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[82]  A. Cadoret,et al.  Hepatomegaly in Transgenic Mice Expressing an Oncogenic Form of β-Catenin , 2001 .

[83]  Kyosuke Yamamoto,et al.  Involvement of the Ets-1 gene in overexpression of matrilysin in human hepatocellular carcinoma. , 2000, Cancer research.

[84]  T. Lu,et al.  Enforced P-glycoprotein pump function in murine bone marrow cells results in expansion of side population stem cells in vitro and repopulating cells in vivo. , 2000, Blood.

[85]  M. Buendia.  Genetics of hepatocellular carcinoma. , 2000, Seminars in cancer biology.

[86]  M. Kay,et al.  Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system , 2000, Nature Genetics.

[87]  Dexi Liu,et al.  Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA , 1999, Gene Therapy.

[88]  Yoshiharu Matsuura,et al.  The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice , 1998, Nature Medicine.

[89]  M. Buendia,et al.  Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[90]  R. Plasterk,et al.  Molecular Reconstruction of Sleeping Beauty , a Tc1-like Transposon from Fish, and Its Transposition in Human Cells , 1997, Cell.

[91]  D. Seol,et al.  Co‐expression and regulation of Met and Ron proto‐oncogenes in human hepatocellular carcinoma tissues and cell lines , 1997, Hepatology.

[92]  Y. Otani,et al.  Difference in gene expression for matrix metalloproteinase‐1 between early and advanced hepatocellular carcinomas , 1997, Hepatology.

[93]  M. Gossen,et al.  Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[94]  T. Gansler,et al.  c-myc amplification in hepatocellular carcinoma predicts unfavorable prognosis. , 1996, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[95]  M. Colombo,et al.  Epidemiology of hepatocellular carcinoma. , 1995, The Italian journal of gastroenterology.

[96]  K. Koike,et al.  High‐level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice , 1994, Hepatology.

[97]  Philippe Soriano,et al.  Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. , 1993, Genes & development.

[98]  G. Jay,et al.  HBx gene of hepatitis B virus induces liver cancer in transgenic mice , 1991, Nature.

[99]  M. Manns,et al.  A critical role for notch signaling in the formation of cholangiocellular carcinomas. , 2013, Cancer cell.

[100]  Zhijian Wu,et al.  Effect of genome size on AAV vector packaging. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[101]  Xin Chen,et al.  Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. , 2009, Cancer research.

[102]  S. Monga,et al.  WNT/beta-catenin signaling in liver health and disease. , 2007, Hepatology.

[103]  J. Licht,et al.  Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling. , 2006, Trends in cell biology.

[104]  Eric C. Olivares,et al.  In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[105]  M. Taketo,et al.  Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. , 2004, Cancer research.

[106]  A. Cadoret,et al.  Hepatomegaly in transgenic mice expressing an oncogenic form of beta-catenin. , 2001, Cancer research.

[107]  M. Kay,et al.  Efficient lentiviral transduction of liver requires cell cycling in vivo , 2000, Nature Genetics.